Veracyte (VCYT) Change in Accured Expenses (2012 - 2026)

Veracyte (VCYT) has 15 years of Change in Accured Expenses data on file, last reported at -$6.1 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 31.15% year-over-year to -$6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (up 149.25% YoY) and the FY2025 annual result came in at $6.3 million, up 78.37% from the prior year.
• Change in Accured Expenses eased to -$6.1 million in Q1 2026 per VCYT's latest filing, from -$718000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $12.9 million in Q2 2024, with the low at -$9.0 million in Q1 2024.
• Average Change in Accured Expenses over 5 years is -$50529.4, with a median of -$351000.0 recorded in 2024.
• Year-over-year, Change in Accured Expenses tumbled 1879.74% in 2023 and jumped 45525.0% in 2025.
• Veracyte's Change in Accured Expenses stood at $2.1 million in 2022, then rose by 29.34% to $2.7 million in 2023, then sank by 112.89% to -$351000.0 in 2024, then plunged by 104.56% to -$718000.0 in 2025, then plunged by 752.37% to -$6.1 million in 2026.
• Business Quant data shows VCYT's Change in Accured Expenses at -$6.1 million in Q1 2026, -$718000.0 in Q4 2025, and $9.1 million in Q3 2025.